Janus Kinases and Autoimmunity: Bridging Pathways to Therapy-Reference-Cited by-同舟云学术

Janus Kinases and Autoimmunity: Bridging Pathways to Therapy

Published:2024-06-05 Issue: Volume: Page:100007
ISSN:2653-6234
Container-title:International Journal of Drug Discovery and Pharmacology
language:
Short-container-title:IJDDP

Author:

Wei Yazi,Zhang Tiantai

Abstract

Review Janus Kinases and Autoimmunity: Bridging Pathways to Therapy Yazi Wei 1, and Tiantai Zhang 1,* State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China * Correspondence: ttzhang@imm.ac.cn Received: 7 February 2024; Revised: 1 March 2024; Accepted: 1 March 2024; Published: 5 June 2024 Abstract: Janus kinase (JAK) is a family of intracellular non-receptor tyrosine kinases with four members (JAK1, JAK2, JAK3, and Tyk2). The JAK-STAT (signal transducer and activator of transcription) pathway is an evolutionary conserved mechanism of transmembrane signal transduction relaying over 50 cytokines signals to regulate the proliferation, immune response, inflammation, and malignancy. The dysfunction of JAK-STAT signaling pathway is directly associated with the pathogenesis of inflammatory and autoimmune disorders, as well as tumor progression. Studies have shown that targeting the JAK family with small-molecule inhibitors can treat inflammatory and autoimmune diseases and myeloproliferative neoplasms. In this review, we discuss the current understanding of the JAK-STAT signaling and approved JAK inhibitors.

Publisher

Australia Academic Press Pty Ltd

Reference87 articles.

1. Banerjee, S.; Biehl, A.; Gadina, M. S.; et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs 2017, 77, 521–546.

2. Hu, X.; Li, J.; Fu, M.; et al. The JAK/STAT signaling oathway: From bench to clinic. Signal. Transduct. Target. Ther. 2021, 6, 402.

3. O’Shea, J.J.; Holland, S.M.L.; Staudt, M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 2013, 368, 161–170.

4. Alunno, A.; Padjen, I.; Fanouriakis, A.; et al. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: Integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cell 2019, 8, 898.

5. Ihle, J.N.; Witthuhn, B.A.; Quelle, F.W.; et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem. Sci. 1994, 19, 222–227.